3tgg
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | [[Image:3tgg.jpg|left|200px]] | |
| - | The | + | <!-- |
| + | The line below this paragraph, containing "STRUCTURE_3tgg", creates the "Structure Box" on the page. | ||
| + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| + | or leave the SCENE parameter empty for the default display. | ||
| + | --> | ||
| + | {{STRUCTURE_3tgg| PDB=3tgg | SCENE= }} | ||
| - | + | ===A novel series of potent and selective PDE5 inhibitor2=== | |
| - | + | ||
| + | <!-- | ||
| + | The line below this paragraph, {{ABSTRACT_PUBMED_21955943}}, adds the Publication Abstract to the page | ||
| + | (as it appears on PubMed at http://www.pubmed.gov), where 21955943 is the PubMed ID number. | ||
| + | --> | ||
| + | {{ABSTRACT_PUBMED_21955943}} | ||
| + | |||
| + | ==About this Structure== | ||
| + | [[3tgg]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3TGG OCA]. | ||
| + | |||
| + | ==Reference== | ||
| + | <ref group="xtra">PMID:021955943</ref><references group="xtra"/> | ||
| + | [[Category: 3',5'-cyclic-GMP phosphodiesterase]] | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Han, S.]] | ||
| + | [[Category: Hydrolase]] | ||
| + | [[Category: Hydrolase-hydrolase inhibitor complex]] | ||
| + | [[Category: Phosphodiesterase]] | ||
Revision as of 06:34, 25 January 2012
A novel series of potent and selective PDE5 inhibitor2
Template:ABSTRACT PUBMED 21955943
About this Structure
3tgg is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
- Hughes RO, Maddux T, Joseph Rogier D, Lu S, Walker JK, Jon Jacobsen E, Rumsey JM, Zheng Y, Macinnes A, Bond BR, Han S. Investigation of the pyrazinones as PDE5 inhibitors: Evaluation of regioisomeric projections into the solvent region. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6348-52. Epub 2011 Aug 31. PMID:21955943 doi:10.1016/j.bmcl.2011.08.106
